Загрузка...
Use of selexipag in a teenage patient with pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a chronic, progressive, multifactorial disease. Currently, combination therapy is an attractive option for PAH management because three pathways (endothelin, nitric oxide, and prostacyclin) are involved in this disease. Selexipag is a novel oral prostacyclin...
Сохранить в:
| Опубликовано в: : | Ann Pediatr Cardiol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wolters Kluwer - Medknow
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7918021/ https://ncbi.nlm.nih.gov/pubmed/33679065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/apc.APC_63_19 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|